| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | 0.0032 | 1 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.002 | 1 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | 0.0011 | 1 |
| mRNA | XMD8-85 | GDSC1000 | pan-cancer | AAC | -0.0018 | 1 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.0011 | 1 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0012 | 1 |
| mRNA | semagacestat | CTRPv2 | pan-cancer | AAC | -0.0011 | 1 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | 0.00066 | 1 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | -0.003 | 1 |
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | -0.0013 | 1 |